ABSTRACT
INTRODUCTION CDR-SB is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer’s disease (AD) clinical trials. Small CDR-SB differences at the end of a trial often lead to controversy in deriving clinically meaningful interpretations.
METHODS We estimated progression-free time participants remained at each 0.5-unit CDR-SB increment in dominantly inherited AD (DIAD) and sporadic AD populations, evaluating its potential as an alternative measure of treatment effects.
RESULTS Progression-free time is longer at CDR-SB ≤ 2.0 (1–2 years) and shorter at CDR-SB ≥ 5 (0.33 or less) in the ADNI cohort. The DIAD cohort showed similar but shorter times. Using progression-free time, continuous lecanemab treatment for three years is estimated to delay disease progression by 0.7 years in the sporadic population.
DISCUSSION Progression-free time provides a benchmark for expressing clinical progression and treatment effects and can be applied particularly during open-label extensions and singlearm trials without placebo comparisons.
Competing Interest Statement
Disclosure of Conflict of Interests Guoqiao Wang is the biostatistics core co-leader for the DIAN-TU. He reports serving on a Data Safety Committee for Amydis Corporate, Abata Therapeutics, and statistical consultant for Eisai inc. and Alector Inc. Eric McDade is the Associate Director of the DIAN-TU. He reports serving on a Data Safety Committee for Eli Lilly and Company and Alector; scientific consultant for Eisai and Eli Lilly and Company; institutional grant support from Eli Lilly and Company, F. Hoffmann-La Roche, Ltd. and Janssen. Chengjie Xiong, reports serving as a statistical consultant for Diadem and for FDA Advisory Committee on Imaging Medical Products. He also receives support from the following grants: NIHGrantAG067505. Randall J. Bateman, is the Director of the DIAN-TU and Principal Investigator of the DIAN-TU-001. He co-founded C2N Diagnostics. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics, blood plasma assay and methods of diagnosing Alzheimer disease with phosphorylation changes) that is licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. R.J.B. has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. He receives research support from the National Institute on Aging of the National Institutes of Health, DIAN-TU Trial Pharmaceutical Partners (Eli Lilly and Company, F. Hoffman-La Roche, Ltd., and Avid Radiopharmaceuticals), Alzheimer Association, GHR Foundation, Anonymous Organization, DIAN-TU Pharma Consortium (Active: Biogen, Eisai, Eli Lilly and Company, Janssen, F. Hoffmann-La Roche, Ltd./Genentech. Previous: AbbVie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, United Neuroscience). He has been an invited speaker for Novartis and serves on the Advisory Board for F. Hoffman La Roche, Ltd. Dr. John Morris reports serving as a consultant for Barcelona Brain Research Center BBRC and Native Alzheimer Disease‐Related Resource Center in Minority Aging Research, Ext Adv Board, serving on a Data Safety Committee for Cure Alzheimer Fund, Research Strategy Council and LEADS Advisory Board, Indiana University. Lon Schneider reports serving on a Data Safety Committee and as a statistical consultant for many companies and the full list is available in the disclosure form. He also receives grant support from NIH. All the other authors reported no conflicts of interest.
Funding Statement
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers U01AG042791, U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), R01AG046179, R01AG053267, R01AG053267-S1, R01AG068319, and 1U01AG059798. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://adni.loni.usc.edu/data-samples/adni-data/ https://dian.wustl.edu/observational-study/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos